Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/14-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women ≥15 years of age who have no known contraindications and have achieved menarche,Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: ~13-27 h (mean 17 h); Norethindrone: ~5-14 h (mean 8 h). Clinical context: steady-state achieved after ~5 days; half-life supports daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized via CYP3A4, undergoes first-pass metabolism and enterohepatic circulation. Norethindrone: reduced to metabolites, conjugated (glucuronidation and sulfation), and excreted in urine and feces.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~50-60% (metabolites); biliary/fecal: ~30-40% (metabolites); unchanged drug <1% in urine.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% bound to serum albumin; Norethindrone: 97-99% bound to albumin (major) and SHBG (minor).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.3-4.2 L/kg (mean 3.5 L/kg); Norethindrone: 2.5-5.0 L/kg (mean 3.8 L/kg). Clinical meaning: extensive distribution into tissues, including reproductive organs.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Ethinyl estradiol ~40-48% (first-pass metabolism); Norethindrone ~50-70% (first-pass metabolism). Food may slightly increase bioavailability.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment recommended in published literature; however, use with caution in patients with severe renal impairment (e GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances. No data for specific GFR-based modifications.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or hepatic tumors. For Child-Pugh class A or B, use with caution; no specific dose adjustment guidelines exist. Discontinue if jaundice or signs of hepatic dysfunction develop.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults: one tablet daily for 28 days. Use only after appropriate evaluation and counseling.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. Elderly-specific dosing not applicable.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI),Cigarette smoking increases cardiovascular risk,Increased risk of cervical cancer (HPV-related),Hepatic neoplasia (benign/malignant) associated with long-term use,Exacerbation of migraine,Depression,Gallbladder disease,Impaired glucose tolerance,Elevated blood pressure,Hereditary angioedema
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal genital bleeding,Hypersensitivity to any component,Age >35 and smoking cigarettes,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal aura at any age,Major surgery with prolonged immobilization
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects; consider avoiding. No other significant food interactions.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Post-marketing studies have not shown an increased risk of birth defects with combined oral contraceptives. However, inadvertent use during early pregnancy is not associated with teratogenicity. Second and third trimesters: Use is contraindicated due to potential adverse effects on fetal development, including estrogenic effects on female fetuses and androgenic effects on male fetuses. There is a risk of fetal genital abnormalities if exposed in utero, though absolute risk is low. Overall, category X designation for use during pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Combined oral contraceptives, including Ortho-Novum, are generally not recommended during breastfeeding, especially in the early postpartum period, due to estrogen-induced reduction in milk production and quality. Small amounts of ethinylestradiol and norethindrone are excreted in breast milk. M/P ratio for ethinylestradiol is approximately 0.15–0.3; for norethindrone, approximately 0.5–1.2. Progestin-only methods are preferred. Use only when no alternative and with caution.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Ortho-Novum is contraindicated in pregnancy. No dose adjustments are recommended because use during pregnancy is not indicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) would theoretically require dose modifications, but since the drug is contraindicated, no adjustment is applicable.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
ORTHO-NOVUM 7/14-28 is a triphasic oral contraceptive with variable doses of norethindrone and ethinyl estradiol. Bleeding irregularities are common, especially in the first few cycles; reassure patients if pregnancy is ruled out. Missed pills increase risk of breakthrough ovulation; refer to package instructions for missed doses. Concomitant use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, starting on the first Sunday after your period begins.,Use backup contraception (e.g., condoms) for the first 7 days of the first cycle.,If you miss a pill, follow the specific instructions in the package insert based on how many you missed and the week of the cycle.,Common side effects include nausea, breast tenderness, and spotting; these often improve after 2-3 cycles.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old.,This medication does not protect against HIV or other sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/14-28 vs ALYACEN 777, answered by our medical review team.
ORTHO-NOVUM 7/14-28 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/14-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/14-28 is: One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/14-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/14-28 is classified as Category C. First trimester: Post-marketing studies have not shown an increased risk of birth defects with combined oral contraceptives. However, inadvertent use during early pregnancy is not . ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.